Our results suggest that IL-6 signaling is associated with MS regardless of disease phenotype, possibly indicating that IL-6 actions are involved in various pathogenetic mechanisms relevant to both RR and progressive MS. This evidence concerns the gene IL6 and myeloid sarcoma.